生物疗法与克罗恩病相关的结肠直肠癌中改善的瘤结果有关
Bhuwan Giri1, Stefan D Holubar1, David Liska1
1Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio.
在结直肠癌手术前用生物疗法治疗克罗恩病患者的无病生存率有所改善. 这表明,生物制剂可能会改变克罗恩病患者的癌症发展途径.
科学领域:
- 胃肠道学和瘤学
- 炎症性肠道疾病研究研究
- 结肠直肠癌病因 结肠直肠癌病因学
背景情况:
- 克罗恩病患者由于慢性炎症而增加结直肠癌 (CRC) 风险.
- 生物疗法是克罗恩病的主要治疗方法.
- 生物治疗对克罗恩氏病患者CRC结局的影响尚不清楚.
研究的目的:
- 检查克罗恩病患者先前生物治疗暴露与CRC结果之间的关联.
- 为了确定生物疗法是否影响克罗恩相关的CRC的生存率和复发率.
主要方法:
- 追溯队列研究,涉及成年克罗恩病患者,患有治疗性手术后的CRC (1998-2020).
- 在癌症诊断之前对生物药物暴露的分析.
- 评估生存和复发的结果.
主要成果:
- 生物暴露与更高的直肠癌发病率和良好到中等差异化的瘤有关.
- 暴露于生物药物的患者表现出明显更高的5年无病生存率 (80%与45%相比).
- 总体生存率和复发率显示,两组之间的数值差异并不显著.
结论:
- 克罗恩病患者的生物治疗与良好的瘤特征相关,并显著改善了5年无疾病生存率.
- 这些发现表明,用生物药物控制炎症可能会影响结肠直肠癌发生.
- 需要进一步的研究来阐明这些观察的基础机制.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Treatment of Ulcerative Colitis in IBD
